Literature DB >> 23065509

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Florence Nguyen-Khac1, Jerome Lambert, Elise Chapiro, Aurore Grelier, Sarah Mould, Carole Barin, Agnes Daudignon, Nathalie Gachard, Stéphanie Struski, Catherine Henry, Dominique Penther, Hossein Mossafa, Joris Andrieux, Virginie Eclache, Chrystèle Bilhou-Nabera, Isabelle Luquet, Christine Terre, Laurence Baranger, Francine Mugneret, Jean Chiesa, Marie-Joelle Mozziconacci, Evelyne Callet-Bauchu, Lauren Veronese, Hélène Blons, Roger Owen, Julie Lejeune, Sylvie Chevret, Hélène Merle-Beral, Véronique Leblondon.   

Abstract

Waldenström's macroglobulinemia is a disease of mature B cells, the genetic basis of which is poorly understood. Few recurrent chromosomal abnormalities have been reported, and their prognostic value is not known. We conducted a prospective cytogenetic study of Waldenström's macroglobulinemia and examined the prognostic value of chromosomal aberrations in an international randomized trial. The main aberrations were 6q deletions (30%), trisomy 18 (15%), 13q deletions (13%), 17p (TP53) deletions (8%), trisomy 4 (8%), and 11q (ATM) deletions (7%). There was a significant association between trisomy of chromosome 4 and trisomy of chromosome 18. Translocations involving the IGH genes were rare (<5%). Deletion of 6q and 11q, and trisomy 4, were significantly associated with adverse clinical and biological parameters. Patients with TP53 deletion had short progression-free survival and short disease-free survival. Although rare (<5%), trisomy 12 was associated with short progression-free survival. In conclusion, the cytogenetic profile of Waldenström's macroglobulinemia appears to differ from that of other B-cell lymphomas. Chromosomal abnormalities may help with diagnosis and prognostication, in conjunction with other clinical and biological characteristics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065509      PMCID: PMC3659998          DOI: 10.3324/haematol.2012.070458

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  27 in total

1.  Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases.

Authors:  H Chang; S Samiee; D Li; B Patterson; C I Chen; A K Stewart; A Keith Stewart
Journal:  Leukemia       Date:  2004-06       Impact factor: 11.528

2.  Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases.

Authors:  E Callet-Bauchu; L Baseggio; P Felman; A Traverse-Glehen; F Berger; D Morel; S Gazzo; C Poncet; C Thieblemont; B Coiffier; J P Magaud; G Salles
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

3.  Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases.

Authors:  C Terré; F Nguyen-Khac; C Barin; M J Mozziconacci; V Eclache; C Léonard; E Chapiro; H Farhat; A Bouyon; P Rousselot; S Choquet; M Spentchian; P Dubreuil; V Leblond; S Castaigne
Journal:  Leukemia       Date:  2006-07-13       Impact factor: 11.528

4.  6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.

Authors:  E M Ocio; R F J Schop; B Gonzalez; S A Van Wier; J M Hernandez-Rivas; N C Gutierrez; R Garcia-Sanz; M J Moro; C Aguilera; J Hernandez; R Xu; P R Greipp; A Dispenzieri; S M Jalal; M Q Lacy; N Gonzalez-Paz; M A Gertz; J F San Miguel; R Fonseca
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

5.  International prognostic scoring system for Waldenstrom macroglobulinemia.

Authors:  Pierre Morel; Alain Duhamel; Paolo Gobbi; Meletios A Dimopoulos; Madhav V Dhodapkar; Jason McCoy; John Crowley; Enrique M Ocio; Ramon Garcia-Sanz; Steven P Treon; Veronique Leblond; Robert A Kyle; Bart Barlogie; Giampaolo Merlini
Journal:  Blood       Date:  2009-02-05       Impact factor: 22.113

6.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

7.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

Review 8.  The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

Authors:  Elaine S Jaffe
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 9.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

10.  Functional assessment of p53 in chronic lymphocytic leukemia.

Authors:  M Le Garff-Tavernier; H Blons; F Nguyen-Khac; M Pannetier; M Brissard; S Gueguen; F Jacob; L Ysebaert; S A Susin; H Merle-Béral
Journal:  Blood Cancer J       Date:  2011-02-25       Impact factor: 11.037

View more
  16 in total

Review 1.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 3.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

Review 4.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

5.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Authors:  Jorge J Castillo; Ramon Garcia-Sanz; Evdoxia Hatjiharissi; Robert A Kyle; Xavier Leleu; Mary McMaster; Giampaolo Merlini; Monique C Minnema; Enrica Morra; Roger G Owen; Stephanie Poulain; Marvin J Stone; Constantine Tam; Marzia Varettoni; Meletios A Dimopoulos; Steven P Treon; Efstathios Kastritis
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

Review 6.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

7.  Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Authors:  Shuhua Yi; Zengjun Li; Dehui Zou; Wenjie Xiong; Heng Li; Rui Cui; Chengwen Li; Yuting Yan; Wei Liu; Rui Lv; Zhen Yu; Weiwei Chen; Yan Xu; Gang An; Huijun Wang; Kun Ru; Tao Cheng; Jianxiang Wang; Lugui Qiu
Journal:  Oncotarget       Date:  2017-12-15

Review 8.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

9.  Candidate genes of Waldenström's macroglobulinemia: current evidence and research.

Authors:  Giada Bianchi; Antonio Sacco; Shaji Kumar; Giuseppe Rossi; Irene Ghobrial; Aldo Roccaro
Journal:  Appl Clin Genet       Date:  2013-07-17

Review 10.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Authors:  Veronica Tisato; Rebecca Voltan; Arianna Gonelli; Paola Secchiero; Giorgio Zauli
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.